CNC, UNH, CVS, HUM Stocks Slip After-Hours — Trump Administration Reportedly Seeks To Scrap Subsidies On Certain Medicare Plans
Shares of Centene (CNC), UnitedHealth (UNH), CVS (CVS), and Humana (HUM) fell after-hours Tuesday after a report that the Trump administration plans to end a $3.6B federal subsidy for Medicare Part D plans post-2026. The subsidy helps keep premiums low for 25M enrollees. The loss of support could pressure margins and enrollment for insurers offering stand-alone Part D plans, though some beneficiaries may shift to Medicare Advantage plans.
How this was made
The 30-second read
Why it matters
Removal of the subsidy may increase premiums, pressure margins, and drive enrollment toward Medicare Advantage plans.
Market read
Immediate price declines for major PDP insurers; sector‑wide reassessment of profitability.
What to watch
Potential for insurers to absorb costs temporarily or negotiate alternative pricing with drug manufacturers.
Background
The $3.6 bn federal subsidy has kept Medicare Part D premiums low; its expiration could reshape the PDP market.
Ticker impact
Centene shares fell 3% after-hours as the Trump administration plans to end the $3.6 bn Medicare Part D subsidy.
Downward pressure on CNC price in near term.
Loss of subsidy reduces revenue and may force premium hikes, hurting competitiveness.
UnitedHealth Group stock slipped (≈1%) after the subsidy termination announcement.
Short‑term downside risk for UNH.
Loss of federal support could increase costs for stand‑alone Part D plans.
CVS Health (via Aetna) fell about 1% after the subsidy phase‑out news.
Near‑term price pressure.
Reduced subsidy erodes profitability of CVS’s prescription‑drug segment.
Humana shares dropped roughly 1% following the subsidy removal report.
Short‑term downside.
Loss of $3.6 bn support could compress margins.
Molina Healthcare stock slipped about 1% after the policy change announcement.
Potential near‑term decline.
Subsidy removal impacts all PDP‑focused insurers.
Market effects
Health‑insurance sector faces margin compression and possible enrollment shifts to Medicare Advantage.
U.S. market may see broader sell‑off in PDP insurers.
Limited to U.S. health‑insurance companies; minimal global spillover.
Counterpoint
If insurers successfully shift customers to Medicare Advantage, the impact could be muted.
Key entities
- governmentTrump administration
Policy maker ending the subsidy.
- mediaWall Street Journal
Source of the policy announcement.
